Document:

EXHIBIT 10.6

CONFIDENTIAL TREATMENT REQUESTED

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND
EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT REQUESTED IS REQUESTED AND IS NOTED
WITH "[CONFIDENTIAL TREATMENT REQUESTED]." AN UNREDACTED VERSION OF THIS
DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                               PATENT AND KNOW-HOW
                             ASSIGNMENT AND LICENSE
                                    AGREEMENT
                                  BY AND AMONG
                             DE MONTFORT UNIVERSITY
                                       AND
                                 SOMANTA LIMITED

<PAGE>

                                                CONFIDENTIAL TREATMENT REQUESTED

              Patent and know-how assignment and licence agreement

THIS AGREEMENT dated March 20, 2003 is between:

(1)      DE MONTFORT UNIVERSITY ("De Montfort University") incorporated as an
         independent higher education corporation under the 1988 Education
         Reform Act and the Further and Higher Education Act 1992 whose
         principal address is The Gateway, Leicester LE1 9BH; and

(2)      SOMANTIS LIMITED ("Somantis") a company incorporated in England and
         Wales whose registered office is at 1 Portland Place, London W1N 1DE,
         England.

RECITALS:

A.       De Montfort University is the exclusive owner of the Patents and
         possesses related Know-how.

B.       De Montfort University is willing to grant to Somantis and Somantis is
         willing to accept, an assignment of the Patents and a licence to use
         the Know-how, in accordance with the provisions of this Agreement.

IT IS AGREED as follows:

1.       Definitions

In this Agreement, the following words shall have the following meanings:

Affiliate             In relation to a Party, means any entity or person which
                      controls, is controlled by, or is under common control
                      with that Party. For the purposes of this definition,
                      "control" shall mean direct or indirect beneficial
                      ownership of 50% (or, outside a Party's home territory,
                      such lesser percentage as is the maximum, permitted level
                      of foreign investment) or more of the share capital, stock
                      or other participating interest carrying the right to vote
                      or to distribution of profits of that entity or person, as
                      the case may be.

Agreement Year        A period of 365 days from and including the Commencement
                      Date, or from and including any anniversary of the
                      Commencement Date or, in respect of any such period that
                      includes a 29th February, 366 days.

Commencement Date     Such date, if any, as may be notified by Somantis to
                      De Montfort University in accordance with the provisions
                      of clause 8.1.

Field                 The treatment of cancer.
<PAGE>

                                                CONFIDENTIAL TREATMENT REQUESTED

Parties               De Montfort University and Somantis, and "Party" shall
                      mean either of them.

Patents               Any and all of the patents and patent applications
                      referred to in Schedule 1, including any continuations,
                      continuations in part, extensions, reissues, divisions,
                      and any patents, supplementary protection certificates and
                      similar rights that are based on or derive priority from
                      the foregoing.

Royalty-bearing       Any and all products in the Field that are manufactured,
Products              sold or otherwise supplied by Somantis and are within any
                      Valid Claim of the Patents.

Territory             The World.

Valid Claim           A claim of a patent or patent application that has not
                      expired or been held invalid or unenforceable by a court
                      of competent jurisdiction in a final and non-appealable
                      judgment.

2.       Grant of rights

2.1      Assignment and Licence. On the Commencement Date subject to the
         provisions of this Agreement, De Montfort University hereby:

         (a)      Agrees to assign the Patents to Somantis; and

         (b)      Grants Somantis an exclusive licence in the Field to use the
                  Know-how, with the right to sub-license, to develop,
                  manufacture, have manufactured, use and sell Royalty-bearing
                  Products in the Field in the Territory.

2.2      Formal assignments and licences. The Parties shall execute such formal
         assignments and licences as may be necessary or appropriate for
         registration with Patent Offices and other relevant authorities in
         particular territories; and in any event, at Somantis' request, De
         Montfort University shall execute an assignment in the form set out in
         Schedule 3. In the event of any conflict in meaning between any such
         assignment or licence and the provisions of this Agreement, the
         provisions of this Agreement shall prevail wherever possible. Prior to
         the execution of the formal assignment(s) and licence(s) (if any)
         referred to above, the Parties shall so far as possible have the same
         rights and obligations towards one another as if such assignment(s) and
         licence(s) had been granted. The Parties shall use reasonable
         endeavours to ensure that, to the extent permitted by relevant
         authorities, this Agreement shall not form part of any public record.

2.3      Reservation of rights. De Montfort University reserves the
         non-exclusive right for itself, to use the Know-how and the Patents in
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         the Field for the purposes of academic, non-commercial research,
         subject to the confidentiality provisions set out in clause 3 below.

3.       Know-how and Confidential Information

3.1      Provision of Know-how. Upon Somantis's reasonable request, De Montfort
         University shall supply Somantis with all Know-how in its possession
         that De Montfort University is at liberty to disclose and has not
         previously been disclosed and which is reasonable necessary or
         desirable to enable Somantis to undertake the further development of
         the Royalty-bearing Products. The Know-how shall be subject to the
         confidentiality provisions of Clause 3.4 and De Montfort University
         shall be bound by such provisions as if the Know-how had been developed
         by Somantis and disclosed to De Montfort University hereunder. If it is
         agreed that any representative of De Montfort University shall travel
         to Somantis's premises in connection with such supply, Somantis shall
         reimburse all travel (at business class rates), accommodation and
         subsistence costs incurred.

3.2      Status of Know-how. Somantis acknowledges that the Know-how is at an
         early stage of development. Accordingly, specific results cannot be
         guaranteed and any results, materials, information or other items
         (together "Delivered Items") provided under this Agreement are provided
         "as is" and without any express or implied warranties, representations
         or undertakings. As examples, but without limiting the foregoing, De
         Montfort University does not give any warranty that Delivered Items are
         of merchantable or satisfactory quality, are fit for any particular
         purpose, comply with any sample or description, or are viable,
         uncontaminated, safe or non-toxic.

3.3      Responsibility for development of Royalty-bearing Products. Somantis
         shall be exclusively responsible for the technical and commercial
         development and manufacture of Royalty-bearing Products and for
         incorporating any modifications or developments thereto that may be
         necessary or desirable and for all Royalty-bearing Products sold or
         supplied, and accordingly Somantis shall indemnify De Montfort
         University in the terms of Clause 7.3.

3.4      Confidentiality obligations. Each Party ("Receiving Party") undertakes:

         (a)      to maintain as secret and confidential all Know-how and other
                  technical or commercial information obtained directly or
                  indirectly from the other Party ("Disclosing Party") in the
                  course of or in anticipation of this Agreement and to respect
                  the Disclosing Party's rights therein,

         (b)      to use the same exclusively for the purposes of this
                  Agreement, and

         (c)      to disclose the same only to those of its employees,
                  contractors and licensees or sublicensees pursuant to this
                  Agreement (if any) to whom and to the extent that such
                  disclosure is reasonably necessary for the purposes of this
                  Agreement.

3.5      Exceptions to obligations. The provisions of Clause 3.4 shall not apply
         to Know-how and other information which the Receiving Party can
         demonstrate by reasonable, written evidence:
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         (a)      was, prior to its receipt by the Receiving Party from the
                  Disclosing Party, in the possession of the Receiving Party and
                  at its free disposal; or

         (b)      is subsequently disclosed to the Receiving Party without any
                  obligations of confidence by a third party who has not derived
                  it directly or indirectly from the Disclosing Party; or

         (c)      is or becomes generally available to the public through no act
                  or default of the Receiving Party or its agents, employees,
                  Affiliates or licensees or sub-licensees; or

         (d)      the Receiving Party is required to disclose to the courts of
                  any competent jurisdiction, or to any government regulatory
                  agency or financial authority, provided that the Receiving
                  Party shall (i) inform the Disclosing Party as soon as is
                  reasonably practicable, and (ii) at the Disclosing Party's
                  request seek to persuade the court, agency or authority to
                  have the information treated in a confidential manner, where
                  this is possible under the court, agency or authority's
                  procedures; or

         (e)      in the case of information disclosed by De Montfort University
                  to Somantis, is disclosed to actual or potential customers for
                  Royalty-bearing Products in so far as such disclosure is
                  reasonably necessary to promote the sale or use of
                  Royalty-bearing Products, provided that the customers sign a
                  written confidentiality undertaking at least as restrictive as
                  Clauses 3.4 and 3.5.

3.6      Disclosure to employees. The Receiving Party shall procure that all of
         its employees, contractors and licensees or sub-licensees pursuant to
         this Agreement (if any) who have access to any of the Disclosing
         Party's information to which Clause 3.4 applies, shall be made aware of
         and subject to these obligations and shall have entered into written
         undertakings of confidentiality at least as restrictive as Clauses 3.4
         and 3.5 and which apply to the Disclosing Party's information.

4.       Payments

4.1      Initial consideration. Within 30 days of the Commencement Date,
         Somantis shall:

         (a)      pay De Montfort University the non-refundable, non-deductible
                  sum of [CONFIDENTIAL TREATMENT REQUESTED]; and

         (b)      pay De Montfort University an amount equal to those costs
                  incurred by De Montfort University in entering the
                  national/regional phase of the prosecution of the Patent
                  together with all other costs incurred in the prosecution of
                  the Patent between the date of this Agreement and the
                  Commencement Date.

4.2      Somantis shall pay De Montfort University [CONFIDENTIAL TREATMENT
         REQUESTED] on the first successful completion of Phase I clinical
         trials of any of the Royalty-bearing Products (defined as a formal
         decision by Somantis or its licensee to commence Phase II trials).
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

4.3      Somantis shall pay De Montfort University [CONFIDENTIAL TREATMENT
         REQUESTED] on the first successful completion of Phase II and III
         trials (defined as the completion of preparation of a dossier to allow
         a formal application for an NDA in the USA, or MAA in the European
         Union, to be made) of any of the Royalty-bearing Products.

4.4      Within 60 days of the date of this Agreement, Somantis shall issue to
         De Montfort University at nominal cost [CONFIDENTIAL TREATMENT
         REQUESTED] such number of fully paid-up ordinary shares in Somantis Ltd
         as represents [CONFIDENTIAL TREATMENT REQUESTED] of the authorised
         share capital of Somantis at the date of such issue. At the date of
         this Agreement, the authorised share capital of Somantis is 100 million
         shares each of 0.1p par value.

4.5      All sums due under this Agreement:-

         (a)      are exclusive of Value Added Tax which where applicable will
                  be paid by Somantis to De Montfort University in addition;

         (b)      shall be paid in pounds sterling by cheque or direct credit
                  transfer made payable to:

                  De Montfort University
                  Account No 87269171
                  Sort Code 60:60:06

                  National Westminster Bank Plc
                  Leicester City Branch
                  14-16 Haymarket
                  Leicester
                  LE1 3NT

         (c)      shall be made without deduction of income tax or other taxes
                  charges or duties that may be imposed, except insofar as
                  Somantis is required to deduct the same to comply with
                  applicable laws. The Parties shall cooperate and take all
                  steps reasonably and lawfully available to them, at the
                  expense of De Montfort University, to avoid deducting such
                  taxes and to obtain double taxation relief. If Somantis is
                  required to make any such deduction it shall provide De
                  Montfort University with such certificates or other documents
                  as it can reasonably obtain to enable De Montfort University
                  to obtain appropriate relief from double taxation of the
                  payment in question; and

         (d)      shall be made by the due date, failing which De Montfort
                  University may charge interest on any outstanding amount on a
                  daily basis at a rate equivalent to [CONFIDENTIAL TREATMENT
                  REQUESTED] above the National Westminster Bank plc base
                  lending rate then in force.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

4.7      Records

4.7.1    Somantis shall keep at its normal place of business detailed and up to
         date records and accounts showing the stage of development of
         Royalty-bearing Products and the quantity, description and value of
         Royalty-bearing Products sold by it, and the amount of sublicensing
         revenues received by it in respect of Royalty-bearing Products, on a
         country by country basis, and being sufficient to ascertain any
         payments due under this Agreement.

4.7.2    Somantis shall make such records and accounts available, on reasonable
         notice, for inspection during business hours by an independent
         chartered accountant nominated by De Montfort University for the
         purpose of verifying the accuracy of any statement or report given by
         Somantis to De Montfort University under this clause 4. The accountant
         shall be required to keep confidential all information learnt during
         any such inspection, and to disclose to De Montfort University only
         such details as may be necessary to report on the accuracy of
         Somantis's statement or report. De Montfort University shall be
         responsible for the accountant's charges.

4.7.3    Somantis shall ensure that De Montfort University has the same rights
         as those set out in this Clause 4.7 in respect of any licensee or
         licence or sublicencee of Somantis that is licensed or sub-licensed
         under the Patents and/or Know-how pursuant to this Agreement.

5.       Commercialisation

5.1      Somantis shall use commercially best efforts to develop and
         commercially exploit Royalty-bearing Products.

5.2      Without prejudice to the generality of Somantis's obligations under
         Clause 5.1, Somantis shall provide at least annually to De Montfort
         University an updated, written development plan, showing all past,
         current and projected activities taken or to be taken by Somantis to
         bring Royalty-bearing Products to market and sell Royalty-bearing
         Products worldwide.

6.       Intellectual property

6.1      Obtain and maintain the Patents. Somantis shall at his own cost and
         expense:

         (a)      co-operate with De Montfort University and endeavour to obtain
                  and maintain valid patents in the name of Somantis pursuant to
                  each of the patent applications listed in Schedule 1 so as to
                  secure the broadest monopoly reasonably available; and

         (b)      pay all renewal fees in respect of the Patents as and when
                  due;

         provided that if Somantis wishes to abandon any such application or not
         to maintain any such Patent (or to cease funding such application or
         Patent) it shall give 6 months' prior written notice to De Montfort
         University and on the expiry of such notice period Somantis shall
         assign back to De Montfort University without charge the patent
         application or patent identified in the notice.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

6.2      Infringement of the Patents

6.2.1    Each Party shall inform the other Party promptly if it becomes aware of
         any infringement or potential infringement of any of the Patents in the
         Field, and the Parties shall consult with each other to decide the best
         way to respond to such infringement.

6.2.2    If the Parties fail to agree on a joint programme of action, including
         how the costs of any such action are to be borne and how any damages or
         other sums received from such action are to be distributed, then
         Somantis shall be entitled to take action against the third party at
         its sole expense and it shall be entitled to all damages or other sums
         received from such action, after reimbursing De Montfort University for
         any reasonable expenses incurred in assisting it in such action. De
         Montfort University shall agree to be joined in any suit to enforce
         such rights subject to being indemnified and secured in a reasonable
         manner as to any costs, damages, expenses or other liability and shall
         have the right to be separately represented by its own counsel at its
         own expense. If the alleged infringement is both within and outside the
         Field, the Parties shall also co-operate with De Montfort University's
         other licensees (if any) in relation to any such action.

6.3      Infringement of third party rights

6.3.1    If any warning letter or other notice of infringement is received by a
         Party, or legal suit or other action is brought against a Party,
         alleging infringement of third party rights in the manufacture, use or
         sale of any Assigned Product or use of any Patents, that Party shall
         promptly provide full details to the other Party, and the Parties shall
         discuss the best way to respond.

6.3.2    Somantis shall have the right but not the obligation to defend such
         suit to the extent that it relates to the Field, and shall have the
         right to settle with such third party, provided that if any action or
         proposed settlement involves the making of any statement, express or
         implied, concerning the validity of any Patent, the consent of De
         Montfort University must be obtained before taking such action or
         making such settlement.

6.3.3    Somantis shall be entitled to deduct from monies payable under this
         Agreement any sums paid to third parties (including without limitation
         damages, payments in settlement of litigation) and costs and expenses
         incurred in relation to any alleged or actual infringement of third
         party rights in the manufacture, use or sale of any Royalty Bearing
         Products.

7.       Warranties and liability

7.1      Warranties by Owner. De Montfort University warrants, represents and
         undertakes as follows:

         (a)      subject to Clause 7.3, it is entitled to assign the Patents
                  and license the Know-how to Somantis as provided for in this
                  Agreement.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         (b)      it has not done, and will not do nor agree to do during the
                  continuation of this Agreement, any of the following things in
                  the Field, if to do so would be inconsistent with the exercise
                  by Somantis of the rights granted to it under this Agreement,
                  namely:

                  (i)      grant or agree to grant any right, title or interest
                           in the Patents or the Know-how or any improvements
                           thereto; or
                  (ii)     assign, mortgage, charge or otherwise transfer any of
                           the Patents or Know-how or (subject to clause 9.3
                           below) any of its rights or obligations under this
                           Agreement.

7.2      No other warranties

7.2.1    Each of Somantis and De Montfort University acknowledges that, in
         entering into this Agreement, it does not do so in reliance on any
         representation, warranty or other provision except as expressly
         provided in this Agreement, and any conditions, warranties or other
         terms implied by statute or common law are excluded from this Agreement
         to the fullest extent permitted by law.

7.2.2    Without limiting the scope of Clause 7.2.1, De Montfort University does
         not give any warranty, representation or undertaking:-

(a)               as to the efficacy or usefulness of the Patents or Know-how;
                  or

(b)               that any of the Patents is or will be valid or subsisting or
                  (in the case of an application) will proceed to grant; or

(c)               that the use of any of the Patents or Know-how, the
                  manufacture, sale or use of the Royalty-bearing Products or
                  the exercise of any of the rights granted under this Agreement
                  will not infringe any other intellectual property or other
                  rights of any other person; or

(d)               that the Know-how or any other information communicated by De
                  Montfort University to Somantis under or in connection with
                  this Agreement will produce Royalty-bearing Products of
                  satisfactory quality or fit for the purpose for which Somantis
                  intended; or

(e)               as imposing any obligation on De Montfort University to bring
                  or prosecute actions or proceedings against third parties for
                  infringement or to defend any action or proceedings for
                  revocation of any of the Patents; or

(f)               as imposing any liability on De Montfort University in the
                  event that any third party supplies Royalty-bearing Products
                  to customers located in the Territory.

7.3      Indemnity. Somantis shall indemnify De Montfort University against any
         loss, damages, costs or expenses which are awarded against or incurred
         by De Montfort University as a result of any claim or threatened claim
         concerning the use by Somantis or any of its licensees or sublicencees
         of the Patents or Know-how or otherwise in connection with the
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         manufacture, use or sale of or any other dealing in any of the
         Royalty-bearing Products by Somantis or its Affiliates any of its
         licensees or sublicencees.

7.4      Liability. Notwithstanding any other provision of this Agreement, no
         Party shall be liable to any other Party to this Agreement in contract,
         tort, negligence, breach of statutory duty or otherwise for any loss,
         damage, costs or expenses of any nature whatsoever incurred or suffered
         by that other party or its Affiliates of an indirect or consequential
         nature including without limitation any economic loss or other loss of
         turnover, profits, business or goodwill.

8.       Duration and Termination

8.1      Commencement and Conditions

8.1.1    This Agreement, including the assignment and licence granted hereunder
         to Somantis, shall come into effect on such date (if any) as Somantis
         shall notify to De Montfort University in accordance with this clause
         8.1 (the "Commencement Date"). Such notification may be given at any
         time on or before 1 September 2002, but may only be given if Somantis
         shall have received at least (pound)1,000,000 (one million pounds
         sterling) by way of proceeds from a subscription for shares in
         Somantis.

8.1.2    During the period between the date of this Agreement and the earlier of
         (a) the Commencement Date and (b) 1 December 2004, De Montfort
         University shall not enter into any agreement or discussions with any
         other person in relation to the assignment or licensing of any or all
         of the Patents and the Know-how.

8.1.3

8.2      Termination by expiry. Unless terminated earlier in accordance with
         this Clause 8, this Agreement and the licence or sub-licences granted
         hereunder shall continue in force until the date on which all the
         Patents have expired or been revoked without a right of further appeal,
         and on such date this Agreement and the licences granted hereunder
         shall terminate automatically by expiry.

8.3      Early termination

8.3.1    Somantis may terminate this Agreement at any time on 90 days notice in
         writing to De Montfort University.

8.3.2    Without prejudice to any other right or remedy, either Party may
         terminate this Agreement at any time by notice in writing to the other
         Party ("Other Party"), such notice to take effect as specified in the
         notice:-

         (a)      if the Other Party is in breach of this Agreement and, in the
                  case of a breach capable of remedy within 90 days, the breach
                  is not remedied within 90 days of the Other Party receiving
                  notice specifying the breach and requiring its remedy; or

         (b)      if the Other Party becomes insolvent, or if an order is made
                  or a resolution is passed for the winding up of the Other
                  Party (other than voluntarily for the purpose of solvent
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                  amalgamation or reconstruction), or if an administrator,
                  administrative receiver or receiver is appointed in respect of
                  the whole or any part of the Other Party's assets or business,
                  or if the Other Party makes any composition with its creditors
                  or takes or suffers any similar or analogous action in
                  consequence of debt.

8.3.3    De Montfort University may forthwith terminate this Agreement by giving
         written notice to Somantis if Somantis or its Affiliate or licensee or
         sub-licensee commences legal proceedings, or assists any third party to
         commence legal proceedings, to challenge the validity of any of the
         Patents.

8.3.4    De Montfort University may terminate the Agreement forthwith if any of
         the payments due and payable under clause 4 of the Agreement are not
         made within 60 days of Somantis receiving from De Montfort University
         notice of default in making such a payment, such notice to refer to
         this clause 8.3.4 and to De Montfort University's intention to
         terminate this Agreement if the payment is not made; and in the event
         of such termination Somantis shall re-assign all Patent Applications to
         De Montfort obligation-free and without charge.

8.3.5    Either party may on giving to the other Party of not less than 10 days'
         written notice prior to 1st December 2004 terminate the Agreement as at
         the 1st December 2004 if the Parties agree (such agreement to be
         entirely at each Party's discretion) that:

         (a)      Royalty-bearing Products are unlikely to arise from pursuance
                  of the Agreement; or

         (b)      it is unlikely that such Royalty-bearing Products will enter
                  Clinical Trials prescribed for under clause 4 above; or

         (c)      for any other reason the objects of this Agreement cannot be
                  commercially achieve;

         in which event the Parties shall have no further obligations to one
         another under this Agreement other than their continuing obligations
         under clauses 3.4 to 3.6 in respect of information disclosed prior to
         the date of termination.

8.4      Consequences of termination

8.4.1    Upon termination of this Agreement by expiry under clause 8.2 above,
         Somantis shall have the non-exclusive right to use the Know-how without
         charge or other obligation to De Montfort University.

8.4.2    Upon termination of this Agreement for any reason otherwise than in
         accordance with Clause 8.2 or 8.3.5:

         (a)      Somantis and its licensee sub-licencees shall be entitled to
                  sell, use or otherwise dispose of any unsold or unused stocks
                  of the Royalty-bearing Products;

         (b)      subject to paragraph (a) above, Somantis shall no longer be
                  entitled as assignee or licensee to use or otherwise exploit
                  in any way, either directly or indirectly, the Patents, in so
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                  far and for as long as any of the Patents remains in force, or
                  the Know-how, and any licence or sub-licences granted by
                  Somantis shall automatically terminate;

         (c)      subject to paragraph (a) above, Somantis shall re-assign the
                  Patents to De Montfort University;

         (d)      the provisions of clauses 3.4 to 3.6 (in respect of
                  information disclosed prior to termination), 4 (in respect of
                  payments becoming due prior to termination), 7 and 9 shall
                  continue in force; and

         (e)      subject as provided in this Clause 8.3.2 and 8.3.3 and 8.3.4,
                  and except in respect of any accrued rights, neither party
                  shall be under any further obligation to the other.

8.4.3    Upon termination of this Agreement for any reason and at De Montfort
         University's request, the Parties shall negotiate in good faith the
         terms of an agreement between them on reasonable commercial terms under
         which Somantis would:

         (a)      transfer to De Montfort University exclusively all clinical
                  and other data relating to the development of Royalty-bearing
                  Products;

         (b)      to the extent possible, seek to have any product licences,
                  pricing approvals and other permits and applications
                  transferred into the name of De Montfort University or its
                  nominee;

         (c)      grant De Montfort University an exclusive, worldwide licence,
                  with the rights to grant licence or sub-licences, under any
                  improvements and other intellectual property owned or
                  controlled by Somantis relating to the Royalty-bearing
                  Products; and

         (d)      grant De Montfort University or its nominee the right to
                  continue to use any product name that had been applied to the
                  Royalty-bearing Products prior to termination of this
                  Agreement.

8.4.4    If the Parties are unable to agree the terms of an agreement as
         described in Clause 8.4.3 within 90 days of De Montfort University
         requesting the negotiation of such an agreement, either Party may refer
         the terms for settlement by an independent expert who shall be
         appointed in accordance with the provisions of Schedule 2 and whose
         decision shall be final and binding on the Parties. The Parties shall
         promptly execute an agreement on the terms agreed between them or
         settled by the expert.

9.       General

9.1      Force majeure. Neither Party shall have any liability or be deemed to
         be in breach of this Agreement for any delays or failures in
         performance of this Agreement which result from circumstances beyond
         the reasonable control of that Party, including without limitation
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         labour disputes involving that Party. The Party affected by such
         circumstances shall promptly notify the other Party in writing when
         such circumstances cause a delay or failure in performance and when
         they cease to do so.

9.2      Amendment. This Agreement may only be amended in writing signed by duly
         authorised representatives of De Montfort University and Somantis.

9.3      Assignment and third party rights.

9.3.1    Except as provided in clause 9.3.2, neither Party may assign or
         transfer any or all of its rights and obligations hereunder.

9.3.2    Either Party may assign all its rights and obligations under this
         Agreement together with its rights in the Patents and the Know-how to
         any company to which it transfers all or part of its assets or
         business, PROVIDED that the assignee undertakes to the other Party to
         be bound by and perform the obligations of the assignor under this
         Agreement.

9.4      Waiver. No failure or delay on the part of either Party to exercise any
         right or remedy under this Agreement shall be construed or operate as a
         waiver thereof, nor shall any single or partial exercise of any right
         or remedy preclude the further exercise of such right or remedy.

9.5      Invalid clauses. If any provision or part of this Agreement is held to
         be invalid, amendments to this Agreement may be made by the addition or
         deletion of wording as appropriate to remove the invalid part or
         provision but other wise retain the provision and the other provisions
         of this Agreement to the maximum extent permissible under applicable
         law.

9.6      No Agency. Neither Party shall act or describe itself as the agent of
         the other, nor shall it make or represent that it has authority to make
         any commitments on the other's behalf.

9.7      Interpretation. In this Agreement:

         (a)      the headings are used for convenience only and shall not
                  affect its interpretation;

         (b)      references to persons shall include incorporated and
                  unincorporated persons; references to the singular include the
                  plural and vice versa; and references to the masculine include
                  the feminine;

         (c)      references to Clauses and Schedules mean clauses of, and
                  schedules to, this Agreement; and

         (d)      references to the grant of "exclusive" rights shall mean that
                  the person granting the rights shall neither grant the same
                  rights (in the same Field and Territory) to any other person,
                  nor exercise those rights directly to the extent that and for
                  as long as the Royalty-bearing Products are within Valid
                  Claims of unexpired Patents.

9.8      Notices
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

9.8.1    Any notice to be given under this Agreement shall be in writing and
         shall be sent by first class mail or air mail, or by fax (confirmed by
         first class mail or air mail) to the address of the relevant Party set
         out at the head of this Agreement, or to the relevant fax number set
         out below, or such other address or fax number as that Party may from
         time to time notify to the other Party in accordance with this Clause
         9.8. The fax numbers of the Parties are as follows: De Montfort
         University - 0116 257 7142; Somantis - 0207 299 9482 .

9.8.2    Notices sent as above shall be deemed to have been received three
         working days after the day of posting (in the case of inland first
         class mail), or seven working days after the date of posting (in the
         case of air mail), or on the next working day after transmission (in
         the case of fax messages, but only if a transmission report is
         generated by the sender's fax machine recording a message from the
         recipient's fax machine, confirming that the fax was sent to the number
         indicated above and confirming that all pages were successfully
         transmitted).

9.9      Law and Jurisdiction. The validity, construction and performance of
         this Agreement shall be governed by English law and shall be subject to
         the exclusive jurisdiction of the English courts to which the parties
         hereby submit, except that a Party may seek an interim injunction in
         any court of competent jurisdiction.

9.10     Further action. Each Party agrees to execute, acknowledge and deliver
         such further instruments, and do all further similar acts, as may be
         necessary or appropriate to carry out the purposes and intent of this
         Agreement.

9.11     Announcements. Neither Party shall make any press or other public
         announcement concerning any aspect of this Agreement, or make any use
         of the name of the other Party in connection with or in consequence of
         this Agreement, without the prior written consent of the other Party.

9.12     Entire agreement. This Agreement, including its Schedules, sets out the
         entire agreement between the Parties relating to its subject matter and
         supersedes all prior oral or written agreements, arrangements or
         understandings between them relating to such subject matter. The
         Parties acknowledge that they are not relying on any representation,
         agreement, term or condition which is not set out in this Agreement.

AGREED   by the parties through their authorised signatories:-

For and on behalf of                      For and on behalf of
DE MONTFORT UNIVERSITY                    SOMANTIS LIMITED

/s/ J. SIMONS                             /s/ AGAMEMNON A. EPENETOS
------------------------------------      --------------------------------------
signed                                    signed

J. Simons                                 Agamemnon A. Epenetos
------------------------------------      --------------------------------------
print name                                print name

                                          CEO
------------------------------------      --------------------------------------
title                                     title

20/3/03                                   20/3/03
------------------------------------      --------------------------------------
date                                      date
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 1
                                   The Patents

International Patent Classification [CONFIDENTIAL TREATMENT REQUESTED]

International Filing Date [CONFIDENTIAL TREATMENT REQUESTED]

Priority Date:    [CONFIDENTIAL TREATMENT REQUESTED]

Applicant: De Montfort University , Leicester

Title: [CONFIDENTIAL TREATMENT REQUESTED]

International Publication Number: [CONFIDENTIAL TREATMENT REQUESTED]

International Publication Date: [CONFIDENTIAL TREATMENT REQUESTED]]

<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 2
                              Appointment of expert

1.       Pursuant to Clause 8.4.4, De Montfort University may serve notice on
Somantis ("Referral Notice") that it wishes to refer to an expert (the "Expert")
the questions set out in Clause 8.4.4.

2.       The parties shall agree the identity of a single independent, impartial
expert to determine such questions. In the absence of such agreement within 30
days of the Referral Notice, the questions shall be referred to an expert
appointed by the President of Law Society of England and Wales.

3.       60 days after the giving of a Referral Notice, both parties shall
exchange simultaneously statements of case in no more than 10,000 words, in
total, and each side shall simultaneously send a copy of its statement of case
to the Expert.

4.       Each party may, within 30 days of the date of exchange of statement of
case pursuant to paragraph 3 above, serve a reply to the other side's statement
of case of not more than 10,000 words. A copy of any such reply shall be
simultaneously sent to the Expert.

5.       The Expert shall make his decision on the said questions on the basis
of written statements and supporting documentation only and there shall be no
oral hearing. The Expert shall issue his decision in writing within 30 days of
the date of service of the last reply pursuant to paragraph 4 above or, in the
absence of receipt of any replies, within 60 days of the date of exchange
pursuant to paragraph 3 above.

6.       The Expert's decision shall be final and binding on the parties.

7.       The Expert's charges shall be borne equally by the parties.CONFIDENTIAL TREATMENT REQUESTED                                    EXHIBIT 10.7

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND
EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT REQUESTED IS REQUESTED AND IS NOTED
WITH "[CONFIDENTIAL TREATMENT REQUESTED]." AN UNREDACTED VERSION OF THIS
DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                               PATENT AND KNOW-HOW
                             ASSIGNMENT AND LICENSE
                                OPTION AGREEMENT
                                  BY AND AMONG
                             THE SCHOOL OF PHARMACY,
                              UNIVERSITY OF LONDON
                                       AND
                                 SOMANTA LIMITED
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

           Patent and know-how assignment and license option agreement

THIS AGREEMENT dated March 16, 2004 is between:

(1)      THE SCHOOL OF PHARMACY ("The School of Pharmacy") incorporated in
         England whose principal address is 28-38 Brunswick Square, London WC1N
         1AX; and

(2)      SOMANTIS LIMITED ("Somantis") a company incorporated in England and
         Wales, (with company number [4201851]) whose registered office is at
         117 Alexandra Park Road, London N10 2DP.

RECITALS:

A.       The School of Pharmacy is the owner of the Patents (as defined below)
         and possesses related Know-how.

B.       The School of Pharmacy is willing to grant to Somantis and Somantis is
         willing to accept, an option to obtain an assignment of the Patents and
         a licence to use the Know-how (as defined below), in accordance with
         the provisions of this Agreement.

C.       Somantis and The School of Pharmacy have entered into a Research
         Collaboration Agreement under which The School of Pharmacy shall
         conduct further research funded by Somantis on the invention(s)
         disclosed by the Patents.

D.       In accordance with the Research Collaboration Agreement between the
         School of Pharmacy and Somantis, Somantis has agreed to pay the patent
         costs.

IT IS AGREED as follows:

1.       Definitions

In this Agreement, the following words shall have the following meanings:

Affiliate                            In relation to a Party, means any entity or
                                     person, which controls, is controlled by,
                                     or is under common control with that Party.
                                     For the purposes of this definition,
                                     "control" shall mean direct or indirect
                                     beneficial ownership of 50% (or, outside a
                                     Party's home territory, such lesser
                                     percentage as is the maximum, permitted
                                     level of foreign investment) or more of the
                                     share capital, stock or other participating
                                     interest carrying the right to vote or to
                                     distribution of profits of that entity or
                                     person, as the case may be.

Field                                The treatment of cancer using the
                                     invention(s) disclosed in the Patents.

                                       2
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

Know-how                             All technical information in the Field
                                     created during research carried out by The
                                     School of Pharmacy under the direction of
                                     Prof. Laurence Patterson in the possession
                                     of The School of Pharmacy relating directly
                                     to the inventions claimed in the Patents.

Option Exercise Date                 Shall have the meaning given in Clause 8.1.

Net Receipts                         The total amounts received by Somantis or
                                     its Affiliates from any person to whom it
                                     grants a licence or sub-licence under the
                                     Patents and/or Know-how (less any Value
                                     Added Tax or other sales tax), excluding
                                     payments made for research work actually
                                     performed, but including without
                                     limitation, up-front payments, milestone
                                     payments, royalties, Premium on Equity from
                                     a licensee or sub-licensee, in each case
                                     reasonably allocable to such licence or
                                     sublicence rights under the Patents and/or
                                     Know-how. "Premium on Equity" means the
                                     amount by which amounts received by
                                     Somantis for a particular equity security
                                     exceed the fair market value of such
                                     security.

Net Sales Value                      The [CONFIDENTIAL TREATMENT REQUESTED]
                                     price of Royalty-bearing Products sold by
                                     Somantis or its Affiliates to independent
                                     third parties in arm's length transactions
                                     exclusively for money or, where the sale is
                                     not at arm's length, the price that would
                                     have been so [CONFIDENTIAL TREATMENT
                                     REQUESTED] if it had been at arm's length,
                                     after deduction of normal trade discounts
                                     actually granted and any credits actually
                                     given and, provided the amounts are
                                     separately charged on the relevant
                                     [CONFIDENTIAL TREATMENT REQUESTED], any
                                     costs of packaging, insurance, carriage and
                                     freight, any value added tax or other sales
                                     tax, and any import duties or similar
                                     applicable government levies.

Parties                              The School of Pharmacy and Somantis, and
                                     "Party" shall mean either of them.

Patents                              Any and all of the patents and patent
                                     applications referred to in Schedule 1,
                                     including any continuations, continuations
                                     in part, extensions, reissues, divisions,
                                     and any patents, supplementary protection
                                     certificates and similar rights that are
                                     based on or derive priority from the
                                     foregoing.

Research Collaboration               A research collaboration agreement between
Agreement                            The School of Pharmacy and Somantis under
                                     which Somantis shall fund further research
                                     by The School of Pharmacy on the
                                     invention(s) disclosed in the Patents on
                                     terms acceptable to both parties.

                                       3
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

Royalty-bearing                      Any and all products in the Field that are
Products                             manufactured, sold or otherwise supplied by
                                     Somantis and are within any Valid Claim of
                                     the Patents or use the Know-how.

Territory                            The World.

Valid Claim                          A claim of a patent or patent application
                                     that has not expired or been held invalid
                                     or unenforceable by a court of competent
                                     jurisdiction in a final and non-appealable
                                     judgment.

2.       Grant of rights

2.1      Grant of Option. The School of Pharmacy hereby grants to Somantis the
         right to purchase and acquire the Patents in accordance with Clause
         8.1.

2.2      Assignment and Licence. On the Option Exercise Date subject to the
         provisions of this Agreement, The School of Pharmacy shall:

         (a)      Assign the Patents to Somantis; and

         (b)      Grant to Somantis an exclusive licence in the Field to use the
                  Know-how, with the right to sub-license, to develop,
                  manufacture, have manufactured, use and sell Royalty-bearing
                  Products in the Field in the Territory.

2.3      Formal assignments and licences. In order to effect the assignments and
         licence contemplated by Clause 2.2, the Parties shall execute such
         formal assignments and licences as may be necessary or appropriate for
         registration with Patent Offices and other relevant authorities in
         particular territories; and in any event, at Somantis' request, The
         School of Pharmacy shall execute an assignment in the form set out in
         Schedule 3. In the event of any conflict in meaning between any such
         assignment or licence and the provisions of this Agreement, the
         provisions of this Agreement shall prevail wherever possible. Prior to
         the execution of the formal assignment(s) and licence(s) (if any)
         referred to above, the Parties shall so far as possible have the same
         rights and obligations towards one another as if such assignment(s) and
         licence(s) had been granted. The Parties shall use reasonable
         endeavours to ensure that, to the extent permitted by relevant
         authorities, this Agreement shall not form part of any public record.

2.4      Reservation of rights. From the Option Exercise Date Somantis grants to
         The School of Pharmacy the non-exclusive right to use the Patents, and
         The School of Pharmacy reserves the non-exclusive right for itself to
         use the Know-how, for the purposes of academic, non-commercial research
         and publication of such research, subject to the confidentiality
         provisions set out in Clause 3 below.

                                       4
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

3.       Know-how and Confidential Information

3.1      Provision of Know-how. Upon Somantis' reasonable request, The School of
         Pharmacy shall supply Somantis with all Know-how in its possession that
         The School of Pharmacy is at liberty to disclose and has not previously
         been disclosed and which is reasonably necessary or desirable to enable
         Somantis to undertake the further development of the Royalty-bearing
         Products. The Know-how shall be subject to the confidentiality
         provisions of Clause 3.4 and The School of Pharmacy shall be bound by
         such provisions as if the Know-how had been developed by Somantis and
         disclosed to The School of Pharmacy hereunder. If it is agreed that any
         representative of The School of Pharmacy shall travel to Somantis'
         premises in connection with such supply, Somantis shall reimburse all
         travel (at business class rates), accommodation and subsistence costs
         incurred.

3.2      Status of Know-how. Somantis acknowledges that the Know-how is at an
         early stage of development. Accordingly, specific results cannot be
         guaranteed and any results, materials, information or other items
         (together "Delivered Items") provided under this Agreement are provided
         "as is" and without any express or implied warranties, representations
         or undertakings. As examples, but without limiting the foregoing, The
         School of Pharmacy does not give any warranty that Delivered Items do
         not infringe third party rights, are of merchantable or satisfactory
         quality, are fit for any particular purpose, comply with any sample or
         description, or are viable, uncontaminated, safe or non-toxic.

3.3      Responsibility for development of Royalty-bearing Products. Somantis
         shall be exclusively responsible for the technical and commercial
         development and manufacture of Royalty-bearing Products and for
         incorporating any modifications or developments thereto that may be
         necessary or desirable and for all Royalty-bearing Products sold or
         supplied, and accordingly Somantis shall indemnify The School of
         Pharmacy in the terms of Clause 7.4.

3.4      Confidentiality obligations. Subject to the terms of this Agreement,
         each Party ("Receiving Party") undertakes:

         (a)      to maintain as secret and confidential all Know-how and other
                  technical or commercial information obtained directly or
                  indirectly from the other Party ("Disclosing Party") in the
                  course of or in anticipation of this Agreement and to respect
                  the Disclosing Party's rights therein,

         (b)      to use the same exclusively for the purposes of this
                  Agreement, and

         (c)      to disclose the same only to those of its employees,
                  contractors and licensees or sublicensees pursuant to this
                  Agreement (if any) to whom and to the extent that such
                  disclosure is reasonably necessary for the purposes of this
                  Agreement.

3.5      Exceptions to obligations. The provisions of Clause 3.4 shall not apply
         to Know-how and other information which the Receiving Party can
         demonstrate by reasonable, written evidence:

                                       5
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         (a)      was, prior to its receipt by the Receiving Party from the
                  Disclosing Party, in the possession of the Receiving Party and
                  at its free disposal; or

         (b)      is subsequently disclosed to the Receiving Party without any
                  obligations of confidence by a third party who has not derived
                  it directly or indirectly from the Disclosing Party; or

         (c)      is or becomes generally available to the public through no act
                  or default of the Receiving Party or its agents, employees,
                  Affiliates or licensees or sub-licensees; or

         (d)      the Receiving Party is required to disclose to the courts of
                  any competent jurisdiction, or to any government regulatory
                  agency or financial authority, provided that the Receiving
                  Party shall (i) inform the Disclosing Party as soon as is
                  reasonably practicable, and (ii) at the Disclosing Party's
                  request seek to persuade the court, agency or authority to
                  have the information treated in a confidential manner, where
                  this is possible under the court, agency or authority's
                  procedures; or

         (e)      in the case of information disclosed by The School of Pharmacy
                  to Somantis, is disclosed to actual or potential customers for
                  Royalty-bearing Products in so far as such disclosure is
                  reasonably necessary to promote the sale or use of
                  Royalty-bearing Products, provided that the customers sign a
                  written confidentiality undertaking at least as restrictive as
                  Clauses 3.4 and 3.5.

3.6      Disclosure to employees. The Receiving Party shall procure that all of
         its employees, contractors and licensees or sub-licensees pursuant to
         this Agreement (if any) who have access to any of the Disclosing
         Party's information to which Clause 3.4 applies, shall be made aware of
         and subject to these obligations and shall have entered into written
         undertakings of confidentiality at least as restrictive as Clauses 3.4
         and 3.5 and which apply to the Disclosing Party's information.

3.7      Right to Publish Notwithstanding the provisions of Clause 3.4, The
         School of Pharmacy shall have the right to use, publish and present the
         Patents and Know-how for academic and research purposes (irrespective
         of applications). The School of Pharmacy will use reasonable endeavours
         to submit material intended for publication which relates to the
         Patents or the Know-how to Somantis in writing not less than thirty
         (30) days in advance of the submission for publication. Somantis may
         request that submission for publication be delayed if Somantis
         reasonably believes that the intended publication would materially
         damage its commercial interests (such as, without limitation, the
         protection of confidential information or the filing of patent
         applications). A delay imposed on submission for publication as a
         result of a request made by Somantis shall not exceed sixty (60) days
         from the date of receipt of the material by Somantis. Notification of
         the request for delay in submission for publication must be received by
         The School of Pharmacy within fourteen (14) days after the receipt of
         the material by Somantis, failing which The School of Pharmacy shall be
         free to assume that Somantis has no objection to the proposed

                                       6
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         publication. Nothing in this Agreement shall prevent any registered
         student of The School of Pharmacy from submitting for a degree of The
         School of Pharmacy or the University of London a thesis based on or
         related to the Patents or the Know-how, the examination of such a
         thesis by examiners appointed by The School of Pharmacy or the
         University of London, or the deposit of such a thesis in a library of
         The School of Pharmacy or the University of London in accordance with
         the relevant procedures of The School of Pharmacy or the University of
         London.

4.       Payments

4.1      Option consideration. Within 30 days of the Option Exercise Date,
         Somantis shall pay The School of Pharmacy the non-refundable,
         non-deductible sum of [CONFIDENTIAL TREATMENT REQUESTED].

4.2      Somantis shall pay The School of Pharmacy [CONFIDENTIAL TREATMENT
         REQUESTED] on the successful completion of animal studies,
         demonstrating efficacy for the drug under development.

4.3      Somantis shall as and when requested by The School of Pharmacy pay The
         School of Pharmacy an amount equal to those costs incurred by The
         School of Pharmacy in applying for and prosecuting the Patents,
         including entering the national/regional phase of the prosecution of
         the Patents together with all other costs incurred in the prosecution
         of the Patents and the legal fees incurred by The School of Pharmacy in
         negotiating this Agreement.

4.4      Somantis shall pay The School of Pharmacy [CONFIDENTIAL TREATMENT
         REQUESTED] on the first successful completion of Phase I clinical
         trials of any of the Royalty-bearing Products (defined as completion of
         the Phase I study.

4.5      Somantis shall pay The School of Pharmacy [CONFIDENTIAL TREATMENT
         REQUESTED] on the first successful completion of Phase II clinical
         trials of any of the Royalty-bearing Products (defined as completion of
         the Phase II study).

4.6      Somantis shall pay The School of Pharmacy [CONFIDENTIAL TREATMENT
         REQUESTED] on the first successful completion of Phase III trials
         (defined as the completion of the Phase III study) of any of the
         Royalty-bearing Products.

4.7      Within 60 days of the date of this Agreement, Somantis shall issue to
         The School of Pharmacy in consideration for the grant of the option in
         Clause 2.1 such number of fully paid-up ordinary shares in Somantis as
         represents [CONFIDENTIAL TREATMENT REQUESTED] of the authorised share
         capital of Somantis at the date of such issue. At the date of this
         Agreement, the authorised share capital of Somantis is 100 million
         shares each of 0.1p par value and therefore The School of Pharmacy
         shall be issued with [CONFIDENTIAL TREATMENT REQUESTED].

                                       7
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

4.8      All sums due under this Agreement:-

         (a)      are exclusive of Value Added Tax which where applicable will
                  be paid by Somantis to The School of Pharmacy in addition;

         (b)      shall be paid in pounds sterling by cheque or direct credit
                  transfer made payable to The School of Pharmacy , University
                  of London;

         (c)      shall be made without deduction of income tax or other taxes
                  charges or duties that may be imposed, except insofar as
                  Somantis is required to deduct the same to comply with
                  applicable laws. The Parties shall cooperate and take all
                  steps reasonably and lawfully available to them, at the
                  expense of The School of Pharmacy, to avoid deducting such
                  taxes and to obtain double taxation relief. If Somantis is
                  required to make any such deduction it shall provide The
                  School of Pharmacy with such certificates or other documents
                  as it can reasonably obtain to enable The School of Pharmacy
                  to obtain appropriate relief from double taxation of the
                  payment in question; and

         (d)      shall be made by the due date, failing which The School of
                  Pharmacy may charge interest on any outstanding amount on a
                  daily basis at a rate equivalent to [CONFIDENTIAL TREATMENT
                  REQUESTED] above the National Westminster Bank plc base
                  lending rate then in force.

4.9      If at any time during the continuation of this Agreement Somantis is
         prohibited from making any of the payments required hereunder by a
         governmental authority in any country then Somantis will within the
         prescribed period for making the said payments in the appropriate
         manner use its best endeavours to secure from the proper authority in
         the relevant country permission to make the said payments and will make
         them within 7 days of receiving such permission. If such permission is
         not received within 30 (thirty) days of Somantis making a request for
         such permission then, at the option of The School of Pharmacy, Somantis
         shall deposit the payments due in the currency of the relevant country
         either in a bank account designated by The School of Pharmacy within
         such country or such payments shall be made to an associated company of
         The School of Pharmacy designated by The School of Pharmacy and having
         offices in the relevant country designated by The School of Pharmacy.

4.10     Records

4.10.1   Somantis shall keep at its normal place of business detailed and up to
         date records and accounts showing the stage of development of
         Royalty-bearing Products and the quantity, description and value of
         Royalty-bearing Products sold by it, and the amount of sublicensing
         revenues received by it in respect of Royalty-bearing Products, on a
         country by country basis, and being sufficient to ascertain any
         payments due under this Agreement.

                                       8
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

4.10.2   Somantis shall make such records and accounts available, on reasonable
         notice, for inspection during business hours by an independent
         chartered accountant nominated by The School of Pharmacy for the
         purpose of verifying the accuracy of any statement or report given by
         Somantis to The School of Pharmacy under this Agreement. The accountant
         shall be required to keep confidential all information learnt during
         any such inspection, and to disclose to The School of Pharmacy only
         such details as may be necessary to report on the accuracy of Somantis'
         statement or report. The School of Pharmacy shall be responsible for
         the accountant's charges if Somantis' statement or report was
         reasonably accurate. If the accountant's report shows that Somantis'
         statement or report was not reasonably accurate, Somantis shall pay to
         The School of Pharmacy a sum equal to the accountant's charges.

4.10.3   Somantis shall ensure that The School of Pharmacy has the same rights
         as those set out in this Clause 4.10 in respect of any licensee or
         licence or sublicencee of Somantis that is licensed or sub-licensed
         under the Patents and/or Know-how pursuant to this Agreement.

5.       Commercialisation

5.1      Somantis shall use all reasonable endeavours to develop and
         commercially exploit Royalty-bearing Products in accordance with the
         development timetable set out in Schedule 4.

5.2      Without prejudice to the generality of Somantis' obligations under
         Clause 5.1, Somantis shall provide at least annually to The School of
         Pharmacy an updated, written development plan, showing all past,
         current and projected activities taken or to be taken by Somantis to
         bring Royalty-bearing Products to market and sell Royalty-bearing
         Products worldwide.

5.3      If Somantis does not achieve a development target within the deadline
         set out in Schedule 4 in relation to the development of Royalty-bearing
         Products, Somantis shall notify The School of Pharmacy within 30 days
         giving reasonable details why such target was not achieved.

5.4      If Somantis does not achieve a development target within six months
         after the deadline set out in Schedule 4, The School of Pharmacy may
         terminate this Agreement with immediate effect on notice to Somantis.

6.       Intellectual property

6.1      Obtain and maintain the Patents. Until the Option Exercise Date, The
         School of Pharmacy shall at his own cost and expense:

         (a)      endeavour to obtain and maintain valid patents in the name of
                  The School of Pharmacy pursuant to each of the patent
                  applications listed in Schedule 1 so as to secure the broadest
                  monopoly reasonably available; and

                                       9
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         (b)      pay all renewal fees in respect of the Patents as and when
                  due.

6.2      On and after the Option Exercise Date, Somantis shall:

         (a)      at its own cost and expense endeavour to maintain valid
                  patents in the name of Somantis pursuant to each of the patent
                  applications listed in Schedule 1 so as to secure the broadest
                  monopoly reasonably available; and

         (b)      pay all renewal fees in respect of the Patents as and when
                  due;

         provided that if Somantis wishes to abandon any such application or not
         to maintain any such Patent (or to cease funding such application or
         Patent) it shall give 6 months' prior written notice to The School of
         Pharmacy and on the expiry of such notice period Somantis shall assign
         back to The School of Pharmacy without charge the patent application or
         patent identified in the notice.

6.3      Infringement of the Patents

6.3.1    Each Party shall inform the other Party promptly if it becomes aware of
         any infringement or potential infringement of any of the Patents in the
         Field, and the Parties shall consult with each other to decide the best
         way to respond to such infringement.

6.3.2    If the Parties fail to agree on a joint programme of action, including
         how the costs of any such action are to be borne and how any damages or
         other sums received from such action are to be distributed, then any
         time after the Option Exercise Date Somantis shall be entitled to take
         action against the third party at its sole expense and it shall be
         entitled to all damages or other sums received from such action, after
         reimbursing The School of Pharmacy for any reasonable expenses incurred
         in assisting it in such action and any damages or sums received from
         such action which relate to the period before the Option Exercise Date.
         The School of Pharmacy shall agree to be joined in any suit to enforce
         such rights subject to being indemnified and secured in a reasonable
         manner as to any costs, damages, expenses or other liability and shall
         have the right to be separately represented by its own counsel at its
         own expense.

6.4      Infringement of third party rights

6.4.1    If any warning letter or other notice of infringement is received by a
         Party, or legal suit or other action is brought against a Party,
         alleging infringement of third party rights in the manufacture, use or
         sale of any Assigned Product or use of any Patents, that Party shall
         promptly provide full details to the other Party, and the Parties shall
         discuss the best way to respond.

6.4.2    Somantis shall have the right but not the obligation to defend such
         suit to the extent that it relates to the Field, and shall have the
         right to settle with such third party, provided that if any action or
         proposed settlement involves the making of any statement, express or
         implied, concerning the validity of any Patent, the consent of The
         School of Pharmacy must be obtained before taking such action or making
         such settlement.

                                       10
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

7.       Warranties and liability

7.1      Warranties by Owner. The School of Pharmacy warrants, represents and
         undertakes as follows:

         (a)      subject to Clause 7.3, it is entitled to assign the Patents
                  and license the Know-how to Somantis as provided for in this
                  Agreement.
         (b)      it has not done, and will not do nor agree to do during the
                  continuation of this Agreement, any of the following things in
                  the Field, if to do so would be inconsistent with the exercise
                  by Somantis of the rights granted to it under this Agreement,
                  namely:

                  (i)      grant or agree to grant any right, title or interest
                           in the Patents or the Know-how or any improvements
                           thereto; or

                  (ii)     assign, mortgage, charge or otherwise transfer any of
                           the Patents or Know-how or (subject to Clause 9.3
                           below) any of its rights or obligations under this
                           Agreement.

7.2      Warranties by Somantis. Somantis warrants, represents and undertakes as
         follows:

         (a)      that Somantis shall not assign, transfer, mortgage, charge or
                  otherwise encumber any of the Patents; and

         (b)      Somantis shall not license the Patents to any party except on
                  terms which include obligations to commercialise the Patents
                  at least as great as in this Agreement and shall provide a
                  copy of any such licence agreement to The School of Pharmacy
                  within 30 days of the grant of the licence.

7.3      No other warranties

7.3.1    Each of Somantis and The School of Pharmacy acknowledges that, in
         entering into this Agreement, it does not do so in reliance on any
         representation, warranty or other provision except as expressly
         provided in this Agreement, and any conditions, warranties or other
         terms implied by statute or common law are excluded from this Agreement
         to the fullest extent permitted by law.

7.3.2    Without limiting the scope of Clause 7.3.1, The School of Pharmacy does
         not give any warranty, representation or undertaking:-

         (a)      as to the efficacy or usefulness of the Patents or Know-how;
                  or

         (b)      that any of the Patents is or will be valid or subsisting or
                  (in the case of an application) will proceed to grant; or

                                       11
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         (c)      that the use of any of the Patents or Know-how, the
                  manufacture, sale or use of the Royalty-bearing Products or
                  the exercise of any of the rights granted under this Agreement
                  will not infringe any other intellectual property or other
                  rights of any other person; or

         (d)      that the Know-how or any other information communicated by The
                  School of Pharmacy to Somantis under or in connection with
                  this Agreement will produce Royalty-bearing Products of
                  satisfactory quality or fit for the purpose for which Somantis
                  intended; or

         (e)      as imposing any obligation on The School of Pharmacy to bring
                  or prosecute actions or proceedings against third parties for
                  infringement or to defend any action or proceedings for
                  revocation of any of the Patents; or

         (f)      as imposing any liability on The School of Pharmacy in the
                  event that any third party supplies Royalty-bearing Products
                  to customers located in the Territory.

7.4      Indemnity. Somantis shall indemnify The School of Pharmacy against any
         loss, damages, costs or expenses which are awarded against or incurred
         by The School of Pharmacy as a result of any claim or threatened claim
         concerning the use by Somantis or any of its licensees or sublicensees
         of the Patents or Know-how or otherwise in connection with the
         manufacture, use or sale of or any other dealing in any of the
         Royalty-bearing Products by Somantis or its Affiliates, any of its
         licensees or sublicensees.

7.5      Liability. Notwithstanding any other provision of this Agreement, no
         Party shall be liable to any other Party to this Agreement in contract,
         tort, negligence, breach of statutory duty or otherwise for any loss,
         damage, costs or expenses of any nature whatsoever incurred or suffered
         by that other party or its Affiliates of an indirect or consequential
         nature including without limitation any economic loss or other loss of
         turnover, profits, business or goodwill.

7.6      Notwithstanding any other provision of this Agreement, The School of
         Pharmacy's total liability to Somantis in contract, tort (including
         negligence), misrepresentation (other than fraudulent
         misrepresentation) or otherwise arising out of or in connection with
         this Agreement shall be limited to [CONFIDENTIAL TREATMENT REQUESTED]
         as at the date of the claim.

8.       Duration and Termination

8.1      Commencement, Option and Conditions

8.1.1    This Agreement shall come into effect on the date of this Agreement.
         The assignment and licence in Clause 2.2, shall come into effect on
         such date on or before 31 October 2004 (if any) as Somantis shall
         notify to The School of Pharmacy in accordance with this Clause 8.1

                                       12
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         (the "Option Exercise Date"). Such notification may be given at any
         time on or before 31 October 2004, but may only be given if:

         (a)      Somantis shall have agreed to receive sufficient funds by way
                  of proceeds from a subscription for shares in Somantis and/or
                  as part of a collaborative agreement, to conduct its business;

         (b)      The School of Pharmacy and Somantis shall have entered into
                  the Research Collaboration Agreement.

8.1.2    During the period between the date of this Agreement and the earlier of
         (a) the Option Exercise Date and (b) 31 October 2004, The School of
         Pharmacy shall not enter into any agreement or discussions with any
         other person in relation to the assignment or licensing of any or all
         of the Patents and the Know-how.

8.1.3    If Somantis fails to give a notification to The School of Pharmacy in
         accordance with Clause 8.1.1, this Agreement shall terminate on 1
         November 2004, the provisions of Clauses 3.4 to 3.6 (in respect of
         information disclosed prior to termination) and 4 (in respect of
         payments becoming due prior to termination) shall continue in force,
         the provisions of Clauses 8.4.2(f) and (g) shall apply and for the
         avoidance of doubt any payments made by Somantis to The School of
         Pharmacy under this Agreement on or prior to 31 October 2004 shall not
         be refundable.

8.2      Termination by expiry. Unless terminated earlier in accordance with
         this Clause 8, this Agreement and the licence or sub-licences granted
         hereunder shall continue in force until the date on which all the
         Patents have expired or been revoked without a right of further appeal,
         and on such date this Agreement and the licences granted hereunder
         shall terminate automatically by expiry.

8.3      Early termination

8.3.1    Somantis may terminate this Agreement at any time on 90 days notice in
         writing to The School of Pharmacy.

8.3.2    Without prejudice to any other right or remedy, either Party may
         terminate this Agreement at any time by notice in writing to the other
         Party ("Other Party"), such notice to take effect as specified in the
         notice:-

         (a)      if the Other Party is in breach of this Agreement and, in the
                  case of a breach capable of remedy within 90 days, the breach
                  is not remedied within 90 days of the Other Party receiving
                  notice specifying the breach and requiring its remedy; or

         (b)      if the Other Party becomes insolvent, or if an order is made
                  or a resolution is passed for the winding up of the Other
                  Party (other than voluntarily for the purpose of solvent
                  amalgamation or reconstruction), or if an administrator,
                  administrative receiver or receiver is appointed in respect of
                  the whole or any part of the Other Party's assets or business,
                  or if the Other Party makes any composition with its creditors
                  or takes or suffers any similar or analogous action in
                  consequence of debt.

                                       13
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

8.3.3    The School of Pharmacy may forthwith terminate this Agreement by giving
         written notice to Somantis if Somantis or its Affiliate or licensee or
         sub-licensee commences legal proceedings, or assists any third party to
         commence legal proceedings, to challenge the validity of any of the
         Patents.

8.3.4    The School of Pharmacy may terminate the Agreement forthwith if any of
         the payments due and payable or issue of shares due under Clause 4 of
         the Agreement are not made within 60 days of Somantis receiving from
         The School of Pharmacy notice of default in making such a payment, such
         notice to refer to this Clause 8.3.4 and to The School of Pharmacy's
         intention to terminate this Agreement if the payment is not made; and
         in the event of such termination Somantis shall assign all Patents to
         The School of Pharmacy in accordance with Clause 8.4.2(c).

8.3.5    Either party may on giving to the other Party of not less than 10 days'
         written notice prior to 1st November 2004 terminate the Agreement if
         the Parties agree (such agreement to be entirely at each Party's
         discretion) that:

         (a)      Royalty-bearing Products are unlikely to arise from pursuance
                  of the Agreement; or

         (b)      it is unlikely that such Royalty-bearing Products will enter
                  Clinical Trials prescribed for under Clause 4 above; or

         (c)      for any other reason the objects of this Agreement cannot be
                  commercially achieved;

         in which event the Parties shall have no further obligations to one
         another under this Agreement other than their continuing obligations
         under Clauses 3.4 to 3.6 in respect of information disclosed prior to
         the date of termination.

8.4      Consequences of termination

8.4.1    Upon termination of this Agreement by expiry under Clause 8.2 above,
         Somantis shall have the non-exclusive right to use the Know-how without
         charge or other obligation to The School of Pharmacy.

8.4.2    Upon termination of this Agreement after the Option Exercise Date for
         any reason otherwise than in accordance with Clause 8.2:

         (a)      Somantis and its licensee sub-licensees shall be entitled to
                  sell, use or otherwise dispose of any unsold or unused stocks
                  of the Royalty-bearing Products;

                                       14
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         (b)      subject to paragraph (a) above, Somantis shall no longer be
                  entitled as assignee or licensee to use or otherwise exploit
                  in any way, either directly or indirectly, the Patents, in so
                  far and for as long as any of the Patents remains in force, or
                  the Know-how, and any licence or sub-licences granted by
                  Somantis shall automatically terminate;

         (c)      Somantis shall free of charge assign the Patents to The School
                  of Pharmacy free from any encumbrances;

         (d)      the provisions of Clauses 3.4 to 3.6 (in respect of
                  information disclosed prior to termination), 4 (in respect of
                  payments becoming due prior to termination), 7.4, 7.5, 7.6,
                  8.4 and 9 shall continue in force;

         (e)      subject as provided in this Clause 8.4, and except in respect
                  of any accrued rights, neither party shall be under any
                  further obligation to the other;

         (f)      Somantis and The School of Pharmacy shall promptly return to
                  the other all written Confidential Information and any other
                  written material containing or reflecting any information
                  included in the Confidential Information (whether provided by
                  the other party, its representatives or advisors or otherwise)
                  and will not retain any copies, extracts or other
                  reproductions in whole or in part of such written material;
                  and

         (g)      all documents, memorandum, notes and other writings whatsoever
                  prepared by Somantis and The School of Pharmacy or their
                  representatives or advisors based on the information included
                  in the Confidential Information shall be destroyed.

8.4.3    Upon termination of this Agreement for any reason and at The School of
         Pharmacy's request, the Parties shall negotiate in good faith the terms
         of an agreement between them on reasonable commercial terms under which
         Somantis would:

         (a)      transfer to The School of Pharmacy exclusively all clinical
                  and other data relating to the development of Royalty-bearing
                  Products;

         (b)      to the extent possible, seek to have any product licences,
                  pricing approvals and other permits and applications
                  transferred into the name of The School of Pharmacy or its
                  nominee;

         (c)      grant The School of Pharmacy an exclusive, worldwide licence,
                  with the rights to grant licence or sub-licences, under any
                  improvements and other intellectual property owned or
                  controlled by Somantis relating to the Royalty-bearing
                  Products; and

         (d)      grant The School of Pharmacy or its nominee the right to
                  continue to use any product name that had been applied to the
                  Royalty-bearing Products prior to termination of this
                  Agreement.

                                       15
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

8.4.4    If the Parties are unable to agree the terms of an agreement as
         described in Clause 8.4.3 within 90 days of The School of Pharmacy
         requesting the negotiation of such an agreement, The School of Pharmacy
         may refer the terms for settlement by an independent expert who shall
         be appointed in accordance with the provisions of Schedule 2 and whose
         decision shall be final and binding on the Parties. The Parties shall
         promptly execute an agreement on the terms agreed between them or
         settled by the expert.

9.       General

9.1      Force majeure. Neither Party shall have any liability or be deemed to
         be in breach of this Agreement for any delays or failures in
         performance of this Agreement which result from circumstances beyond
         the reasonable control of that Party, including without limitation
         labour disputes involving that Party. The Party affected by such
         circumstances shall promptly notify the other Party in writing when
         such circumstances cause a delay or failure in performance and when
         they cease to do so.

9.2      Amendment. This Agreement may only be amended in writing signed by duly
         authorised representatives of The School of Pharmacy and Somantis.

9.3      Assignment and third party rights.

9.3.1    Except as provided in Clause 9.3.2, neither Party may assign or
         transfer any or all of its rights and obligations hereunder.

9.3.2    Either Party may assign all its rights and obligations under this
         Agreement together with its rights in the Patents and the Know-how to
         any company to which it transfers all or substantially all of its
         assets or business and in the case of The School of Pharmacy, to any of
         its Affiliates, PROVIDED that the assignee undertakes to the other
         Party to be bound by and perform the obligations of the assignor under
         this Agreement.

9.4      Waiver. No failure or delay on the part of either Party to exercise any
         right or remedy under this Agreement shall be construed or operate as a
         waiver thereof, nor shall any single or partial exercise of any right
         or remedy preclude the further exercise of such right or remedy.

9.5      Invalid clauses. If any provision or part of this Agreement is held to
         be invalid, amendments to this Agreement may be made by the addition or
         deletion of wording as appropriate to remove the invalid part or
         provision but other wise retain the provision and the other provisions
         of this Agreement to the maximum extent permissible under applicable
         law.

9.6      No Agency. Neither Party shall act or describe itself as the agent of
         the other, nor shall it make or represent that it has authority to make
         any commitments on the other's behalf.

                                       16
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

9.7      Interpretation. In this Agreement:

         (a)      the headings are used for convenience only and shall not
                  affect its interpretation;

         (b)      references to persons shall include incorporated and
                  unincorporated persons; references to the singular include the
                  plural and vice versa; and references to the masculine include
                  the feminine;

         (c)      references to Clauses and Schedules mean clauses of, and
                  schedules to, this Agreement; and

         (d)      references to the grant of "exclusive" rights shall mean that
                  the person granting the rights shall neither grant the same
                  rights (in the same Field and Territory) to any other person,
                  nor exercise those rights directly to the extent that and for
                  as long as the Royalty-bearing Products are within Valid
                  Claims of unexpired Patents.

9.8      Notices

9.8.1    Any notice to be given under this Agreement shall be in writing and
         shall be sent by first class mail or air mail, or by fax (confirmed by
         first class mail or air mail) to the address of the relevant Party set
         out at the head of this Agreement, or to the relevant fax number set
         out below, or such other address or fax number as that Party may from
         time to time notify to the other Party in accordance with this Clause
         9.8. The fax numbers of the Parties are as follows: The School of
         Pharmacy - 0207 753 5968; Somantis - 0207 299 9482 .

9.8.2    Notices sent as above shall be deemed to have been received three
         working days after the day of posting (in the case of inland first
         class mail), or seven working days after the date of posting (in the
         case of air mail), or on the next working day after transmission (in
         the case of fax messages, but only if a transmission report is
         generated by the sender's fax machine recording a message from the
         recipient's fax machine, confirming that the fax was sent to the number
         indicated above and confirming that all pages were successfully
         transmitted).

9.9      Law and Jurisdiction. The validity, construction and performance of
         this Agreement shall be governed by English law and shall be subject to
         the exclusive jurisdiction of the English courts to which the parties
         hereby submit, except that a Party may seek an interim injunction in
         any court of competent jurisdiction.

9.10     Further action. Each Party agrees to execute, acknowledge and deliver
         such further instruments, and do all further similar acts, as may be
         necessary or appropriate to carry out the purposes and intent of this
         Agreement.

                                       17
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

9.11     Somantis hereby appoints The School of Pharmacy as its attorney to
         effect on its behalf any assignment of the Patents provided for in this
         Agreement and to do all and any acts and things necessary to effect
         unconditionally such assignment.

9.12     Announcements. Neither Party shall make any press or other public
         announcement concerning any aspect of this Agreement, or make any use
         of the name of the other Party in connection with or in consequence of
         this Agreement, without the prior written consent of the other Party.

9.13     Entire agreement. This Agreement, including its Schedules, sets out the
         entire agreement between the Parties relating to its subject matter and
         supersedes all prior oral or written agreements, arrangements or
         understandings between them relating to such subject matter. The
         Parties acknowledge that they are not relying on any representation,
         agreement, term or condition which is not set out in this Agreement.

AGREED by the parties through their authorised signatories:-

For and on behalf of                             For and on behalf of
THE SCHOOL OF PHARMACY                           SOMANTIS LIMITED

/s/ JULIAN C. AXE                                /s/ AGAMEMNON A. EPENETOS
----------------------------------              --------------------------------
signed                                           signed

          Julian C. Axe                                Agamemnon A. Epenetos
----------------------------------              --------------------------------
print name                                       print name

          Clerk to Council                             CEO
----------------------------------              --------------------------------
title                                            title

          16/3/2004                                    16/3/2004
----------------------------------              --------------------------------
date                                             date

                                       18
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 1
                                   The Patents

[CONFIDENTIAL TREATMENT REQUESTED]

                                       19
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 2
                              Appointment of expert

1.       Pursuant to Clause 8.4.4, The School of Pharmacy may serve notice on
Somantis ("Referral Notice") that it wishes to refer to an expert (the "Expert")
the questions set out in Clause 8.4.4.

2.       The parties shall agree the identity of a single independent, impartial
expert to determine such questions. In the absence of such agreement within 30
days of the Referral Notice, the questions shall be referred to an expert
appointed by the President of Law Society of England and Wales.

3.       60 days after the giving of a Referral Notice, both parties shall
exchange simultaneously statements of case in no more than 10,000 words, in
total, and each side shall simultaneously send a copy of its statement of case
to the Expert.

4.       Each party may, within 30 days of the date of exchange of statement of
case pursuant to paragraph 3 above, serve a reply to the other side's statement
of case of not more than 10,000 words. A copy of any such reply shall be
simultaneously sent to the Expert.

5.       The Expert shall make his decision on the said questions on the basis
of written statements and supporting documentation only and there shall be no
oral hearing. The Expert shall issue his decision in writing within 30 days of
the date of service of the last reply pursuant to paragraph 4 above or, in the
absence of receipt of any replies, within 60 days of the date of exchange
pursuant to paragraph 3 above.

6.       The Expert's decision shall be final and binding on the parties.

7.       The Expert's charges shall be borne equally by the parties.

                                       20
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 3

THIS DEED OF ASSIGNMENT dated __________________2004 is made by and between:-

    (1)      [    ]        whose address is ______; and

    (2)      SOMANTIS LIMITED ("Somantis") whose registered office is at 117
             Alexander Park Road, London N10 2DP

     WHEREAS:

A.   ...   has made application(s) for Patent(s) (defined below as the "Patents"
     in relation to certain inventions and generated related know-how in the
     field of prevention and treatment of cancer through the use of specific
     classes of drugs (together with the "Technology").

B.   ....  is willing to assign its right title and interest in the Patents to
     Somantis subject to the provisions of the Agreement.

THIS DEED OF ASSIGNMENT WITNESSES as follows:-

1.       Definitions
         -----------

         In this Assignment, "Patents" shall mean the patent(s) and patent
         application(s) identified in the attached Schedule.

2.       Assignment
         ----------

2.1      In consideration of the sum of (pound)1 sterling paid to (receipt of
         which they each hereby acknowledge), hereby assign and transfer to
         Somantis absolutely all their right, title and interest in the Patents.

                                       21
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

2.2      The assignments effected by this Clause 2 shall include, without
         limitation, the assignment and transfer of:

         a.       all patents and other patents that may be granted pursuant to
                  any applications listed in the attached Schedule, as well as
                  all patents and other Patents that may derive priority from or
                  have equivalent claims to the applications listed in the
                  Schedule or be based upon the Technology in any country of the
                  world (and including supplementary protection certificates,
                  divisions, continuations, continuations in part, reissues and
                  extensions), and the Patents shall be deemed to include all
                  such items of property;

         b.       and all rights of action, powers and benefits arising from
                  ownership of the Patents, including without limitation the
                  right to sue for damages and other legal and equitable
                  remedies in respect of all causes of action arising prior to,
                  on or after the date of this assignment.

2.3      ........shall execute such documents and give such assistance as
         Somantis may require, at the Somantis' expense:

         a.       to secure the vesting in Somantis of all rights in the
                  Patents;

         b.       to uphold Somantis' rights in the Patents: and

         c.       to defeat any challenge to the validity of, and resolve any
                  questions concerning, the Patents

         d.       All reasonable costs and expenses of is undertaking any of its
                  obligations under this clause shall be paid for and reimbursed
                  in full by Somantis.

3.0      Law and Jurisdiction
         --------------------

The validity, construction and performance of this Assignment shall be governed
by English law, and Somantis submit to the exclusive jurisdiction of the English
courts in respect of any dispute arising in connection therewith.

EXECUTED AS A DEED by the parties:

Executed and delivered as a Deed by by (applying its common seal in the presence
of two members of its Council

                               ______________________signature of Council member

                               ______________________signature of Council member

                                       22
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

Executed and delivered as a Deed by Somantis Limited:

                               __________________________Director's signature0

                               __________________________date

SCHEDULE

Description of general subject area covered by this assignment:

The present invention concerns a novel family of anthraquinone alkylating
agents, their use in the treatment of cancers, methods of manufacture of
medicaments for same, and methods of treatment of cancers.

Description of specific patents and patent applications:

Patent details:   International Patent Classification o

                  International Filing o

                  Priority Date:  [CONFIDENTIAL TREATMENT REQUESTED]

                  Applicant: The School of Pharmacy , London

                  Title: [CONFIDENTIAL TREATMENT REQUESTED]

                  Application Number: [CONFIDENTIAL TREATMENT REQUESTED]

                                       23
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 4
                              Development Timetable

--------------------------------------------------------------------------------

            Development Target                            Deadline
            ------------------                            --------
         [CONFIDENTIAL TREATMENT                  [CONFIDENTIAL TREATMENT
                REQUESTED]                               REQUESTED]
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

                                       24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]